Prometic Life Sciences - Durststrecke ade!

Liebe Mitleser,

nachdem Prometic eine harte Durststrecke hinter sich gelassen hat und der Kurs dies auch widerspiegelt, mehren sich die Anzeichen dafür, dass 2011 und 2012 die bisher besten Jahre in der Unternehmensgeschichte werden könnten. Deswegen dieser neue Thread, da der alte namentlich etwas irreführend erscheint: Prometic ist mit Genta nicht zu vergleichen!
Zahlreiche Partnerschaften mit namhaften Pharmagrößen und Vertriebsspezialisten, Unterstützung verschiedener Regierungen und des Roten Kreuzes sowie eine zuletzt beschlossene Zusammenarbeit mit Allist Pharmaceuticals aus China machen dieses Unternehmen top interessant.
Sollten sich die Prognosen bewahrheiten und Prometic Ende dieses Jahres Lizenzzahlungen seines italienischen Partners Kedrion erhalten, dann sind alle Weichen auf Break-even gestellt.
Des Weiteren wartet man auf eine Entscheidung der britischen Regierung, ob der Einsatz von P-Capt-Filtern bei Blutentnahmen/-Spenden/-transfusionen gesetzlich vorgeschrieben werden soll - von einem Feuerwerk zu sprechen wäre dann schlicht untertrieben.
Und zum Schluss noch hier die letzte Pressemitteilung zum Bau einer neuen Fertigungsanlage, veröffentlicht am 08.02.2011 auf der Homepage:
http://www.prometic.com/docs/events/...ic_Laval_Facility_EN_FINAL.pdf
Lasst uns hier fundierte Prognosen veröffentlichen und daraus realistische Kursziele ableiten...

Beste Grüße,
Oki-Wan 2.0  

So liebe Freunde.
Ich werde mich in der nächsten Zeit voll auf dieses Thema konzentrieren.
Falls also jemand Fragen, Anmerkungen oder Korrekturen bezüglich diesem Thema hat, soll er/sie dies frei und ungezwungen kund tun. Ich freue mich auf jedes partizipieren.

Beste Grüße,
Oki-Wan 2.0  

 

Was sagt man dazu? Unser kleiner P-Capt -Filter erhält wieder mehr Aufmerksamkeit. Bitte richtet euer Augenmerk auf die letzten beiden Absätze des Auszugs:

Posted on February 20, 2011

ProMetic would like to bring to your attention a recently published article by Dr. R. Knight of the UK National CJD Surveillance Unit.

The article is titled "The risk of transmitting prion disease by blood or plasma products".

Points to note include the following sections 5. What can be done? that touches on four broad possible protective actions:  donor selection, donation testing, infectivity inactivation and infectivity removal, and 6. Summary which is listed below.

   6. Summary

   Blood from vCJD donors contains infectivity that can be transmitted to recipients via red cell transfusion and, probably, via other products, including plasma and plasma derivatives.  Many precautionary measures have been introduced but the magnitude of risk remains uncertain due to several unknowns, not least the uncertainty of the number of infected individuals in the general population.

There are no currently validated blood tests for prion infectivity.  Blood prion filters have been developed and their adoption into clinical transfusion practice is being considered.

The P-Capt® prion filter, co-developed by ProMetic and MacoPharma SA, has been commercially available since 2006, and is the only proven approach to reducing the risk of vCJD transmission from red blood cell concentrate.

© Elsevier LTd. doi: 10.1016/j.transci.2010.09.003 Transfusion and Apheresis Science Journal 43 (2010) 387-391

Quelle:
http://www.prometic.com/en/prometic/information.php  

Also nochmal für alle:
Die Brisanz dieser News liegt in der Aussage des Dr. Knight, dass es momentan keine nachweislich geprüften Bluttests für Prioneninfektionen gibt:
"There are no currently validated blood tests for prion infectivity. "

Und das hier ist ein Faktenhammer:
Der P-Capt-Filter,..., ist seit 2006 verfügbar und der einzige nachweislich geprüfte Methode zur Risikominderung von vCJD-Übertragungen durch rote Blutkörper:
"The P-Capt® prion filter, co-developed by ProMetic and MacoPharma SA, has been commercially available since 2006, and is the only proven approach to reducing the risk of vCJD transmission from red blood cell concentrate."

Also kommt die Frage auf:
Worauf warten die Verantwortlichen noch? Auf Selbstheilung?
Der Einsatz der Filter ist schon längst überfällig!

Beste Grüße,
Oki-Wan 2.0  

Das sind Prometics Partner (nur Sumitomo kann ich nicht entdecken, sind aber m.W. noch dabei):

 

About ProMetic

Partners

ProMetic is a  world leader in Protein Technologies and in the  development of  therapeutics. The cross-section  below is representative  of some of the collaborations and agreements between  ProMetic and its  partners and / or clients. These are at various phases of development  worldwide. Each one contributes to building a  strong and diversified  portfolio of business opportunities as well as providing  ProMetic with  long-standing relationships.

 

 

 

Bitte schaut euch doch mal alle den Kurs in Toronto an: 0,225 CAD !!!

Heute kam diese News raus:

 

Press Releases

 

ProMetic on target for its plasma-derived therapeutics business

• Second tranche of funds received; brings total investment in NewCo to date at $1.5 M
• ProMetic's headquarters on schedule to move to NewCo's facility by end of March
• NewCo's manufacturing facility on target to commence operations by end of 2011

MONTREAL, QUEBEC, CANADA - February 28, 2011 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic")  announced today that the Company received a second $750,000  investment  tranche for its new subsidiary NewCo.  This brings the total equity  investment received to date to $1,500,000, as part of a $2,500,000  commitment. 

On February 7, 2011, ProMetic announced that it had  created NewCo to enter into a long-term lease on very favorable  conditions for an existing state-of-the-art facility and to undertake  the development and manufacturing of high-value plasma-derived  therapeutic biosimilars for ProMetic's current and future clients.  This  facility, located in Laval, Quebec's biotech cluster, will have a  targeted processing capacity of 150,000 L, allowing the supply of  products with a market value exceeding $100,000,000 per annum.

The  Company also disclosed that NewCo would be funded via third-party  investments; with ProMetic's existing clients it is anticipated that  NewCo will rapidly become self-sustaining through end product services  and sales.

"This enabling project for ProMetic is attracting  significant interest from strategic players and investors," stated  Pierre Laurin, ProMetic's President and Chief Executive Officer.

NewCo  will allow the Company to benefit, at commercial scale, from the  competitive advantage provided by its proven Plasma Protein Purification  System ("PPPS^TM") as well as its prion capture  technologies.  The manufacturing plant will supply plasma-derived  therapeutic products to ProMetic's existing and future clients, as well  as allowing ProMetic to provide technology transfer and skills training  services. The plant is expected to start up operations by the end of  2011, provide cGMP products to be used by clients in early 2012, and  reach full operating capacity by 2014.

"The preparatory work for  the relocation of ProMetic's headquarters to NewCo's facility has  already started and the move should be completed by the end of March,"  commented Bruce Pritchard, ProMetic's Chief Financial Officer.

About the Plasma Protein Purification System   
The Plasma Protein Purification System ("PPPS^TM")  allows for the targeting and removal of multiple high-value proteins  from a single plasma sample at unprecedented activity levels using  ProMetic's Mimetic Ligand^TM adsorbent technology.  This  system also provides for the recovery of new biotherapeutics as they are  discovered and identified. The effect of this process is to reduce the  significant losses incurred when using the more conventional Cohn  precipitation process

About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (http://www.prometic.com/)  is a biopharmaceutical company specialized in the research,  development, manufacture and marketing of a variety of commercial  applications derived from its proprietary Mimetic Ligand^TM  technology. This technology is used in large-scale purification of  biologics and the elimination of pathogens. ProMetic is also active in  therapeutic drug development with the mission to bring to market  effective, innovative, lower cost, less toxic products for the treatment  of hematology and cancer. Its drug discovery platform is focused on  replacing complex, expensive proteins with synthetic "drug-like" protein  mimetics. Headquartered in Montréal (Canada), ProMetic has R&D  facilities in the UK, the U.S. and Canada, manufacturing facilities in  the UK and business development activities in the U.S., Europe, Asia and  in the Middle-East.

Forward Looking Statements        
This  press release contains forward-looking statements about ProMetic's  objectives, strategies and businesses that involve risks and  uncertainties. These statements are "forward-looking" because they are  based on our current expectations about the markets we operate in and on  various estimates and assumptions. Actual events or results may differ  materially from those anticipated in these forward-looking statements if  known or unknown risks affect our business, or if our estimates or  assumptions turn out to be inaccurate. Such risks and assumptions  include, but are not limited to, ProMetic's ability to develop,  manufacture, and successfully commercialize value-added pharmaceutical  products, the availability of funds and resources to pursue R&D  projects, the successful and timely completion of clinical studies, the  ability of ProMetic to take advantage of business opportunities in the  pharmaceutical industry, uncertainties related to the regulatory process  and general changes in economic conditions. You will find a more  detailed assessment of the risks that could cause actual events or  results to materially differ from our current expectations on page 24 of  ProMetic's Annual Information Form for the year ended December 31,  2009, under the heading "Risk Factors".  As a result, we cannot  guarantee that any forward-looking statement will materialize. We assume  no obligation to update any forward-looking statement even if new  information becomes available, as a result of future events or for any  other reason, unless required by applicable securities laws and  regulations.  All amounts are in Canadian dollars unless stated  otherwise.

 

Allen Investierten viel Glück!

Mit besten Grüßen,
Oki-Wan 2.0  

da hab ich ne weile zu tun und bemerke pli's aufstieg net. bin endlich im plus, und wie... werde auf keinsten verkaufen, die behalte ich jetzt noch bis jahresende wenn die zahlungen von kedrion verbucht sind.
oki, danke für dein gespür. du hast mich auf die aktie gebracht ;-)  

Nach diesem tollen Anstieg waren Gewinnmitnahmen eh zu erwarten. Aber der Kurs hält sich und wird nach einer kleinen Konsolidierung weiter steigen. So wie vorher, in kleinen Schritten.
Das Volumen der letzten Tage war jedenfalls eine Augenweide und spricht für die gesteigerte Aufmerksamkeit für unsere PLI bei den Anlegern.

Allen weiterhin viel Glück und Beste Grüße,
Oki-Wan 2.0  

Hier nochmal die Vorstellung von PBI-1402, neben P-Capt und der Purification-Technologie der Hoffnungsträger bei PLI:

 

Anemia – PBI 1402

ProMetic’s lead candidate drug, PBI-1402, addresses substantial unmet medical needs.

• PBI-1402 is orally active, whereas most other drugs treating anemia are injectables.
• PBI-1402 has shown anticancer activity in multiple pre-clinical models.
• PBI-1402, all the while mimicking EPO’s biological activity,  has a distinct mechanism of action from EPO, as it does not bind to the  same cell surface receptor as EPO. It therefore provides great promise  of serving as a stand-alone therapeutic in the treatment of patients  with anemia.
• PBI-1402 is an affordable low molecular weight synthetic candidate drug, relative to costly recombinant proteins, such as EPO.
• PBI-1402 addresses a worldwide marketplace that exceeds $15 billion.

PBI-1402 for the treatment of Anemia indications

The initial indication targeted by PBI-1402 is anemia in cancer  patients undergoing chemotherapy. Upwards of two thirds of cancer  patients treated with chemotherapy develop anemia. Treatment with EPO,  the current drug of choice for this indication, is active in only 50 to  60 percent of these patients.

PBI-1402 has reported positive clinical results in the  chemotherapy-induced anemia trial and demonstrated excellent safety and  tolerability, as well as an impressive efficacy profile. A Phase II  trial of PBI-1402 demonstrated a significant increase in the red blood  cell count and the hemoglobin level in patients with  chemotherapy-induced anemia (“CIA”). In this open-label Phase II trial,  patients each received PBI-1402 once daily at doses ranging from 44mg/kg  to 88mg/kg. Analysis of the data showed that only 2 patients out of 28  (7%) treated with PBI-1402 required a RBC transfusion, a response rate  greater than 90% with regards to this clinical objective. In the March  13, 2008 FDA briefing document, the Oncology Drugs Advisory Committee  emphasizes that the primary objective of treating CIA patients with  erythropoiesis-stimulating agents (“ESAs”) as being the ability to  reduce the need for RBC transfusion. The Advisory Committee cites that  approximately 50% of anemic patients receiving chemotherapy required RBC  transfusion, and 20%-25% of patients treated with ESAs still required  RBC transfusions.

The encouraging positive results from the CIA clinical trial and  the anticancer effects reported in animal models seem to indicate that  PBI-1402 is well suited for the treatment of anemia in oncology,  resulting in the PBI-1402 clinical platform being extended to patients  suffering from cancer-related anemia. Moreover, approximately twenty  million patients in the U.S. alone are diagnosed with chronic kidney  diseases (“CKD”). Patients diagnosed at severe CKD stages (3 and 4)  often develop anemia before they require hemodialysis. CKD patients  still at the pre-dialysis stage could greatly benefit from an orally  administered drug as a treatment for their anemia.

Recent experiments based on a 5/6 nephrectomized rat model have  demonstrated the ability of PBI-1402 to correct anemia. This model  simulates chronic renal failure in humans, a condition whereby the  kidneys fail to produce sufficient EPO for the stimulation of red blood  cell production. These results indicate additional potential for  PBI-1402.

 

Ist manchem schon aufgefallen, dass sich seit einiger Zeit auf der PBI-1402-Seite ein Link namens "Fact Sheet" mit dem Zusatz "forthcoming" schmückt?
Ich denke, es wird Zeit für PLI auch hier den Schleier zu lüften. Die letzte Meldung zu PBI-1402 wurde in Zusammenhang mit der Kooperationsvereinbarung mit Allist Pharmac. veröffentlicht. Mir wurde mal gesagt, PLI sei ein "One-Trick-Pony" und ich habe damals dem zugestimmt. Jedoch revidiere ich jetzt diese Aussage. Prometic hat mehrere heisse Produkte bzw. Produktkandidaten und längst nicht mehr von dem Erfolg eines Produktes abhängig.

Hier der Link:
http://www.prometic.com/en/therapeutics/anemia-PBI-1402.php

Beste Grüße,
Oki-Wan 2.0  

Beste Grüße,

Oki-Wan 2.0

ProMetic Corporate Update

MONTREAL, QUEBEC, CANADA - March 8, 2011 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic")  today announced, that on the back of its growing operations, the  Company has elected to split the roles of Chairman and Chief Executive  Officer.  Mr. G.F. Kym Anthony has agreed to accept the position of  Chairman of the Board of Directors in order to better support ProMetic's  Chief Executive Officer with the execution of key value drivers during  2011.  Mr. Anthony has been a longtime serving member of ProMetic's  Board of Directors.

"This is a pivotal year for ProMetic.  The  level of moving parts involved in the execution of ProMetic's strategic  plan for our different business units requires the undivided attention  of Mr. Pierre Laurin, our President and Chief Executive Officer. The  recently created NewCo subsidiary for the manufacturing of  plasma-derived therapeutics is just one example of what is expected to  create shareholder value this year," stated Mr. Anthony who went on to  add: "ProMetic's Board of Directors fully supports Mr. Laurin's vision  for the Company.  As Chairman, I will devote more time to support the  Chief Executive Officer and to manage the Board and governance functions  of the business".

Mr. Laurin commented: "I am delighted that Kym  has decided, amongst his various options, to make ProMetic's future  growth his priority. The Company will benefit, through Kym's increased  involvement, from the additional wealth of experience that he brings to  the position of Chairman and to the building of value for corporations.   In addition, ProMetic is demonstrating best corporate governance  practices by separating the role of Chairman of the Board from that of  Chief Executive Officer".

Over the last two years, the Company has  appointed a Board member to act as Lead Director in support of the  Chief Executive Officer and as liaison with the Board and Mr. Benjamin  Wygodny served in this capacity.  With the Company's continued growth,  the separation of the roles of Chairman and Chief Executive Officer is  now formalized through Mr. Anthony's nomination as Chairman, in effect  replacing the position of Lead Director.  Mr. Wygodny will continue in  his mandate as a Director on ProMetic's Board.

About Mr. G.F. Kym Anthony        
Mr.  G.F. Kym Anthony is an experienced and successful capital markets  executive with over 30 years in the financial services and investment  banking industries. He rose through the senior executive ranks of CIBC  and its investment bank unit, Wood Gundy.  He later became the Chair and  Chief Executive Officer of TD Securities and a Vice-Chair of TD Bank,  where he led the creation and development of TD Securities. Mr. Anthony  was also the President and Chief Executive Officer of National Bank  Financial, the investment banking and capital markets unit of National  Bank of Canada for six years and CEO of Dundee Securities. Mr. Anthony  has held a number of senior positions in the financial services  industry, including being Chair of the Investment Dealers Association of  Canada, and serves on several corporate and nonprofit boards.  Mr.  Anthony is also currently Chairman of Broadacre Agriculture and DFG  Investment Advisors and a board member of ComDev International.

 

http://www.prometic.com/en/news-events/...ic-corporate-update-637.php

 

Aus dem letzten Posting:
"This is a pivotal year for ProMetic.  The  level of moving parts involved in the execution of ProMetic's strategic  plan for our different business units requires the undivided attention  of Mr. Pierre Laurin, our President and Chief Executive Officer. The  recently created NewCo subsidiary for the manufacturing of  plasma-derived therapeutics is just one example of what is expected to  create shareholder value this year," stated Mr. Anthony who went on to  add: "ProMetic's Board of Directors fully supports Mr. Laurin's vision  for the Company.  As Chairman, I will devote more time to support the  Chief Executive Officer and to manage the Board and governance functions  of the business".

Entschuldigt mich bitte, aber diese Äußeruung geht bei mir runter wie Butter.
Und "Pivotal Year for Prometic" kann ich nur unterstreichen; bei denen wird sich dieses Jahr, wie ich schon vorher geschrieben habe, ziemlich vieles ändern. Hoffen wir weiterhin, dass es die Shares explodieren lässt. Ich warte nun auf die Entscheidungen des britischen Unterhauses zur P-Capt-Einführung und den ersten Lizenzzahlungen von Kedrion.

Beste Grüße,
Oki-Wan 2.0  

       

New Event Announcement IBC's Biopharmaceutical Development and Production Week Since 1987 ProMetic BioSciences Ltd  (PBL) has been pioneering design, development and manufacture of  affinity purification technology for large scale commercial  bioprocessing as well as research and development at lab-scale in the  biotechnology industry. Come see us at booth #306 at the IBC Biopharmaceutical Development and Production Week  conference taking  place March 16-18 at the Hyatt Regency Bellevue in  Bellevue, Washington.  The conference offers the highest quality and  most in-depth coverage of  the latest technical and scientific advances  in bioprocessing to help  companies (of all sizes) improve the speed,  quality and cost of  developing and producing antibodies. Stop by our booth to learn more about PBL's creative affinity chromatography adsorbents. Albumin Fusion Toolbox-  a range of synthetic affinity adsorbents utilized in development and  commercial scale regulated purification processes for albumin and  albumin related proteins (e.g. albumin fusion proteins). Fabsorbent™- a synthetic affinity adsorbent for purification of a diverse range of fragmented antibodies. Aminophenylboronate- a synthetic affinity adsorbent for glycoprotein separation. p-Aminobenzamidine- a  synthetic  affinity adsorbent for protease contaminant removal. HIC Media- a full  range of five adsorbents for protein purification. Mimetic Ligands™- adsorbents for the capture and purification of proteins derived from various sources. PrioClear™- a panel of affinity adsorbents that enable the highly effective capture of prion from a range of biological materials. QuickScreen- a ligand screening program that quickly allows the  screening of PBL off-the-shelf products as well as the full panel of  Diverse Libraries if required.   Where & When Venue: Hyatt Regency Bellevue, Bellevue Washington  Conference: March 16-18 Booth: #306 Book a Meeting  To make an appointment to meet with representatives of PBL at the Biopharmaceutical Development and Production Week conference, click here.   Corporate Site Links Applications & Products   About Us Applications & Products Shop Services Literature & Downloads Events Antibody & AntibodyFragments Albumin & AlbuminFusion Proteins Glycoprotein Separation Plasma Proteins Prion Removal Other Proteins Contaminant Reduction Protease Removal Endotoxin Removal Glycoprotein Removal Pathogen Reduction Nucleic Acid Purification - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - - ProMetic BioSciences Ltd is a private company limited by shares, incorporated in the Isle of Man with registered number 034251C. The company is also registered as a foreign company at Companies House in the UK, with registration number FC027128. ProMetic BioSciences UK is the branch name of ProMetic BioSciences Ltd, and is registered as a Branch in England & Wales with registration number BR009067.  The registered office of ProMetic BioSciences UK and ProMetic BioSciences Ltd is Freeport, Ballasalla, Isle of Man, IM9 2AP, British Isles.  The liability of the members of ProMetic BioSciences Ltd is limited. Copyright © 2010 ProMetic BioSciences Ltd All rights reserved.

 

Liebe Mitleser,
ich kann es nicht oft genug sagen/schreiben, aber der Kurs wird in Übersee gemacht, siehe hier:
http://tmx.quotemedia.com/quote.php?qm_symbol=PLI&locale=en

Auf die Kurse in Frankfurt und Co. gebe ich nicht einmal einen feuchten ..., ihr wisst schon was. Umgerechnet liegen wir bei knapp über 15 Eurocent!!! bzw. 0,205 CAD.

Weiter geht's mit PLI und wie immer alles Gute den hier Investierten.

Beste Grüsse,
Oki-Wan 2.0  

pli scheint vorerst den boden gefunden zu haben. weit unter 19-20 dollarcent wirds wahrscheinlich nicht gehen. die nächsten news werden wieder für ne vertikale bewegung sorgen, aber nach oben.
wann wird genau die knete von kedrion erwartet?  

du bist noch dabei?
Freut mich auf jeden Fall. Ich dachte nämlich, dass du mit Gewinn ausgestiegen bist.
Ok. Aber jetzt kein OFFTOPIC mehr.
Die Sachen zu Kedrion werde ich hier reinstellen, sobald ich sie gefunden habe (suche das ursprüngliche Agreement).

Bis dahin beste Grüße an alle,
Oki-Wan 2.0  

Hier ist wie versprochen die Pressemitteilung zu Kedrion vom 25.02.2008. Es fehlt aber noch der Teil, welcher die besagten Revenues für Prometic ab 2011 erwartet. Diese liefere ich noch nach. Soweit ich mich erinnere waren diese auf einem Quartals-/Jahresbericht aufgelistet.

Beste Grüße, Oki-Wan 2.0

( http://www.prometic.com/en/news-events/...tive-license-452.php?y=2008 )

ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products

• Kedrion has in-licensed ProMetic's yield improving technology
• $30 M potential annual revenue derived from ProMetic sales of the first hyperimmune product in the U.S. market 
• Incorporation of ProMetic's technology in Kedrion's manufacturing process

MONTREAL, QUEBEC (CANADA) - February 26, 2008 - ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI)  announced today that it has signed the definitive agreement for  development of two hyperimmunes with Kedrion S.p.A. ("Kedrion"). 

Terms  of this agreement call for upfront and milestone payments, as well as  service fees to ProMetic.  Potential revenues to ProMetic from Hepatitis  B Hyperimmune direct sales in North America are to exceed $30 M  annually, which are expected to commence in 2011.

The first  product to be developed will target the Hepatitis B Hyperimmune market  which is currently estimated in Europe and in the U.S. to be at $200 M  and is expected to be at $400 M by 2015.

Kedrion has in-licensed  ProMetic's technologies for the manufacturing of hyperimmune products in  Europe. Royalties, licensing and service fees for the sales of products  in Europe will be paid by Kedrion to ProMetic with ProMetic retaining  the commercial rights for the fully developed hyperimmune products for  the North American market.  ProMetic will in turn pay Kedrion royalties  on its sales of the hyperimmune products in North America.

The  product development program, including the clinical trial designed to  meet U.S. and European regulatory requirements will be funded by  Kedrion, who will be the holder of the products registration for both  markets.

"This agreement with Kedrion will leverage ProMetic's  ability to penetrate into the North American hyperimmune product market  and expand on our existing revenue base," commented Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic.

More about Hepatitis B

HB,  hepatitis B IVIG is primarily used in preventing reinfection with  hepatitis B in HBV positive liver transplant patients. It is also used  in the treatment of acute exposure to hepatitis B following acute  exposure to blood containing HBsAg, perinatal exposure of infants born  to HBsAg-positive mothers, sexual exposure to HBsAg positive persons,  and household exposure of infants to persons with acute hepatitis B  virus infection. The groups usually considered at risk are hepatitis B  researchers and workers, and many health care professionals.

More about Kedrion S.p.A. 
Kedrion (http://www.kedrion.com/)  is a biopharmaceutical company specialized in the development,  production, commercialization and distribution of plasma-derived  products. Born in 2001 following the rationalisation and upgrading of  other companies working in this field, it acquired a heritage of  expertise that secures it a prominent role in Italy, in Europe and in  the world.  Kedrion is present in over 40 countries. It's head office is  in Tuscany, Castelvecchio Pascoli, near Lucca.

In Italy, Kedrion  is a partner of the National Health Service for the production of  plasma-derived medicinal products. In addition, its expertise serves  other strategic partnerships with health institutions in other  countries.

Kedrion's activities are carried on through different  companies and three authorized production plants: Bolognana, near Lucca  (Tuscany); S. Antimo, near Naples; Gödöllő, near Budapest.  Kedrion  works in four business areas: production and commercialization of  plasma-derived products obtained from the plasma fractionation process;  commercialization of flu vaccines and synthetic pharmaceutical products;  plasma collection and commercialization in foreign markets; other  activities, among them in particular transfer of technological know-how.  The three principal types of plasma-derived products produced by  Kedrion are: standard and hyperimmune immunoglobulin, albumin and  coagulation factors (procoagulants and anticoagulants).

About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (http://www.prometic.com/)  is a biopharmaceutical company specialized in the research,  development, manufacture and marketing of a variety of commercial  applications derived from its proprietary Mimetic Ligand(TM) technology.  This technology is used in large-scale purification of biologics and  the elimination of pathogens. ProMetic is also active in therapeutic  drug development with the mission to bring to market effective,  innovative, lower cost, less toxic products for the treatment of  hematology and cancer. Its drug discovery platform is focused on  replacing complex, expensive proteins with synthetic "drug-like" protein  mimetics. Headquartered in Montréal (Canada), ProMetic has R&D  facilities in the UK, the USA and Canada, manufacturing facilities in  the UK and business development activities in the USA, Europe, Asia and  in the Middle-East.

 

Manchmal ist man vor lauter Eifer blind, steht doch im zweiten Absatz der Meldung ganz deutlich
"Potential revenues to ProMetic from Hepatitis  B Hyperimmune direct sales in North America are to exceed $30 M  annually, which are expected to commence in 2011.
The first  product to be developed will target the Hepatitis B Hyperimmune market  which is currently estimated in Europe and in the U.S. to be at $200 M  and is expected to be at $400 M by 2015."

Also nochmal: ab 2011 werden Revenues durch den Verkauf in Nordamerika erwartet; das Potential wird auf 200 Mio. $ geschätzt, 2015 auf 400 Mio $ (Europa und USA).
Es wird also in erster Linie auf Einnahmen aus dem Nordamerika-Geschäft hingewiesen. Kedrion hat mit Prometic eine Abmachung getroffen, um die Hyperimmune-Produkte in Europa vertreiben zu können. Dafür werden sie Prometic Lizenzgebühren etc. zahlen. Prometic wiederum zahlt an Kedrion eine bestimmte Gebühr, abhängig von der Höhe der Einnahmen in Nordamerika.

Beste Grüße,
Oki-Wan 2.0  

Heute per Mail erhalten. Viel Spaß beim lesen und beste Grüße,

Oki-Wan 2.0

 

   

New Event Announcement 4th Annual BioPharma Asia Convention 2011 Since 1987 ProMetic BioSciences Ltd  (PBL) has been pioneering design, development and manufacture of  affinity purification technology for large scale commercial  bioprocessing as well as research and development at lab-scale in the  biotechnology industry. Come see us at the 4th Annual BioPharma Asia Convention  taking  place March 28-31 at the Marina Bay Sands in Singapore.  From  partnering to  drug discovery, manufacturing and clinical trial,  BioPharma Asia brings  you the latest developments in Asia that allow  you to be on top of your  game. More importantly, with so many senior  decision makers gathering at  one place, it is the event to see and be  seen. Stop by our booth to learn more about PBL's creative affinity chromatography adsorbents. Albumin Fusion Toolbox-  a range of synthetic affinity adsorbents utilized in development and  commercial scale regulated purification processes for albumin and  albumin related proteins (e.g. albumin fusion proteins). Fabsorbent™- a synthetic affinity adsorbent for purification of a diverse range of fragmented antibodies. Aminophenylboronate- a synthetic affinity adsorbent for glycoprotein separation. p-Aminobenzamidine- a  synthetic  affinity adsorbent for protease contaminant removal. HIC Media- a full  range of five adsorbents for protein purification. Mimetic Ligands™- adsorbents for the capture and purification of proteins derived from various sources. PrioClear™- a panel of affinity adsorbents that enable the highly effective capture of prion from a range of biological materials. QuickScreen- a ligand screening program that quickly allows the  screening of PBL off-the-shelf products as well as the full panel of  Diverse Libraries if required.   Where & When Venue: Marina Bay Sands, Singapore  Conference: March 28-31 Book a Meeting  To make an appointment to meet with representatives of PBL at the 4th Annual BioPharma Asia Convention, click here.

 

ist hier eine Übersicht zu den Messen, auf denen Prometic Bio vertreten sein wird.

Einen schönen Abend wünsche ich allen,

Oki-Wan 2.0

 

 

PBL are proud to support the following key industry event(s). Come meet us at the following conferences:

 

 

 

 

 

Mit besten Grüßen,

Oki-Wan 2.0

 

New Event Announcement BioProcess International Europe Conference and Exhibition Since 1987 ProMetic BioSciences Ltd  (PBL) has been pioneering design, development and manufacture of  affinity purification technology for large scale commercial  bioprocessing as well as research and development at lab-scale in the  biotechnology industry. Come see us at the BioProcess International Europe Conference and Exhibition  taking  place April 6-7th at the Nice Acropolis Des Congres, Nice  France.  Europe's largest bioprocessing conference, the BioProcess  International Europe Conference and Exhibition brings together  innovation, science and solutions to drive every stage of  biomanufacturing.   Stop by our booth to learn more about PBL's creative affinity chromatography adsorbents. Albumin Fusion Toolbox-  a range of synthetic affinity adsorbents utilized in development and  commercial scale regulated purification processes for albumin and  albumin related proteins (e.g. albumin fusion proteins). Fabsorbent™- a synthetic affinity adsorbent for purification of a diverse range of fragmented antibodies. Aminophenylboronate- a synthetic affinity adsorbent for glycoprotein separation. p-Aminobenzamidine- a  synthetic  affinity adsorbent for protease contaminant removal. HIC Media- a full  range of five adsorbents for protein purification. Mimetic Ligands™- adsorbents for the capture and purification of proteins derived from various sources. PrioClear™- a panel of affinity adsorbents that enable the highly effective capture of prion from a range of biological materials. QuickScreen- a ligand screening program that quickly allows the  screening of PBL off-the-shelf products as well as the full panel of  Diverse Libraries if required.   Where & When Venue: Nice Acropolis Des Congres, France Conference: April 6-7 Book a Meeting  To make an appointment to meet with representatives of PBL at the BioProcess International Europe Conference and Exhibition, click here.

Corporate Site Links	Applications & Products
About Us Applications & Products Shop Services Literature & Downloads Events	Antibody & AntibodyFragments Albumin & AlbuminFusion Proteins Glycoprotein Separation Plasma Proteins Prion Removal Other Proteins	Contaminant Reduction Protease Removal Endotoxin Removal Glycoprotein Removal Pathogen Reduction Nucleic Acid Purification

 

- - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - -

 

 

warum heute der handel ausgesetzt war?
habe was im netz gefunden aber nicht schlauer geworden
es ist von einer nicht eingehaltenen frist die rede (annual report 2010)